COVID-19 Impact on Global Adoptive Cellular Immunotherapy Market Size, Status and Forecast 2020-2026

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Adoptive Cellular Immunotherapy Revenue
• 1.4 Market Analysis by Type
  • 1.4.1 Global Adoptive Cellular Immunotherapy Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 TIL
  • 1.4.3 LAK
  • 1.4.4 CAR-T
  • 1.4.5 TCR-T
  • 1.4.6 CIK
  • 1.4.7 NK
  • 1.4.8 DC
  • 1.4.9 Other
• 1.5 Market by Application
  • 1.5.1 Global Adoptive Cellular Immunotherapy Market Share by Application: 2020 VS 2026
  • 1.5.2 Hospital
  • 1.5.3 Cancer Hospital
  • 1.5.4 Centers for Disease Control and Prevention
  • 1.5.5 Rehabilitation Center
  • 1.5.6 Other
• 1.6 Coronavirus Disease 2019 (Covid-19): Adoptive Cellular Immunotherapy Industry Impact
  • 1.6.1 How the Covid-19 is Affecting the Adoptive Cellular Immunotherapy Industry
    • 1.6.1.1 Adoptive Cellular Immunotherapy Business Impact Assessment - Covid-19
    • 1.6.1.2 Supply Chain Challenges
    • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  • 1.6.2 Market Trends and Adoptive Cellular Immunotherapy Potential Opportunities in the COVID-19 Landscape
  • 1.6.3 Measures / Proposal against Covid-19
    • 1.6.3.1 Government Measures to Combat Covid-19 Impact
    • 1.6.3.2 Proposal for Adoptive Cellular Immunotherapy Players to Combat Covid-19 Impact
• 1.7 Study Objectives
• 1.8 Years Considered

2 Global Growth Trends by Regions

• 2.1 Adoptive Cellular Immunotherapy Market Perspective (2015-2026)
• 2.2 Adoptive Cellular Immunotherapy Growth Trends by Regions
  • 2.2.1 Adoptive Cellular Immunotherapy Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Adoptive Cellular Immunotherapy Historic Market Share by Regions (2015-2020)
  • 2.2.3 Adoptive Cellular Immunotherapy Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Adoptive Cellular Immunotherapy Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Adoptive Cellular Immunotherapy Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Adoptive Cellular Immunotherapy Players by Market Size
  • 3.1.1 Global Top Adoptive Cellular Immunotherapy Players by Revenue (2015-2020)
  • 3.1.2 Global Adoptive Cellular Immunotherapy Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Adoptive Cellular Immunotherapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Adoptive Cellular Immunotherapy Market Concentration Ratio
  • 3.2.1 Global Adoptive Cellular Immunotherapy Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Adoptive Cellular Immunotherapy Revenue in 2019
• 3.3 Adoptive Cellular Immunotherapy Key Players Head office and Area Served
• 3.4 Key Players Adoptive Cellular Immunotherapy Product Solution and Service
• 3.5 Date of Enter into Adoptive Cellular Immunotherapy Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

• 4.1 Global Adoptive Cellular Immunotherapy Historic Market Size by Type (2015-2020)
• 4.2 Global Adoptive Cellular Immunotherapy Forecasted Market Size by Type (2021-2026)

5 Adoptive Cellular Immunotherapy Breakdown Data by Application (2015-2026)

• 5.1 Global Adoptive Cellular Immunotherapy Market Size by Application (2015-2020)
• 5.2 Global Adoptive Cellular Immunotherapy Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Adoptive Cellular Immunotherapy Market Size (2015-2020)
• 6.2 Adoptive Cellular Immunotherapy Key Players in North America (2019-2020)
• 6.3 North America Adoptive Cellular Immunotherapy Market Size by Type (2015-2020)
• 6.4 North America Adoptive Cellular Immunotherapy Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Adoptive Cellular Immunotherapy Market Size (2015-2020)
• 7.2 Adoptive Cellular Immunotherapy Key Players in Europe (2019-2020)
• 7.3 Europe Adoptive Cellular Immunotherapy Market Size by Type (2015-2020)
• 7.4 Europe Adoptive Cellular Immunotherapy Market Size by Application (2015-2020)

8 China

• 8.1 China Adoptive Cellular Immunotherapy Market Size (2015-2020)
• 8.2 Adoptive Cellular Immunotherapy Key Players in China (2019-2020)
• 8.3 China Adoptive Cellular Immunotherapy Market Size by Type (2015-2020)
• 8.4 China Adoptive Cellular Immunotherapy Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Adoptive Cellular Immunotherapy Market Size (2015-2020)
• 9.2 Adoptive Cellular Immunotherapy Key Players in Japan (2019-2020)
• 9.3 Japan Adoptive Cellular Immunotherapy Market Size by Type (2015-2020)
• 9.4 Japan Adoptive Cellular Immunotherapy Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Adoptive Cellular Immunotherapy Market Size (2015-2020)
• 10.2 Adoptive Cellular Immunotherapy Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Adoptive Cellular Immunotherapy Market Size by Type (2015-2020)
• 10.4 Southeast Asia Adoptive Cellular Immunotherapy Market Size by Application (2015-2020)

11 India

• 11.1 India Adoptive Cellular Immunotherapy Market Size (2015-2020)
• 11.2 Adoptive Cellular Immunotherapy Key Players in India (2019-2020)
• 11.3 India Adoptive Cellular Immunotherapy Market Size by Type (2015-2020)
• 11.4 India Adoptive Cellular Immunotherapy Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Adoptive Cellular Immunotherapy Market Size (2015-2020)
• 12.2 Adoptive Cellular Immunotherapy Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Adoptive Cellular Immunotherapy Market Size by Type (2015-2020)
• 12.4 Central & South America Adoptive Cellular Immunotherapy Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 Amgen Inc
  • 13.1.1 Amgen Inc Company Details
  • 13.1.2 Amgen Inc Business Overview and Its Total Revenue
  • 13.1.3 Amgen Inc Adoptive Cellular Immunotherapy Introduction
  • 13.1.4 Amgen Inc Revenue in Adoptive Cellular Immunotherapy Business (2015-2020))
  • 13.1.5 Amgen Inc Recent Development
• 13.2 Autolus Therapeutics Plc
  • 13.2.1 Autolus Therapeutics Plc Company Details
  • 13.2.2 Autolus Therapeutics Plc Business Overview and Its Total Revenue
  • 13.2.3 Autolus Therapeutics Plc Adoptive Cellular Immunotherapy Introduction
  • 13.2.4 Autolus Therapeutics Plc Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
  • 13.2.5 Autolus Therapeutics Plc Recent Development
• 13.3 Beijing Immunochina Medical Science & Technology Co Ltd
  • 13.3.1 Beijing Immunochina Medical Science & Technology Co Ltd Company Details
  • 13.3.2 Beijing Immunochina Medical Science & Technology Co Ltd Business Overview and Its Total Revenue
  • 13.3.3 Beijing Immunochina Medical Science & Technology Co Ltd Adoptive Cellular Immunotherapy Introduction
  • 13.3.4 Beijing Immunochina Medical Science & Technology Co Ltd Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
  • 13.3.5 Beijing Immunochina Medical Science & Technology Co Ltd Recent Development
• 13.4 Bellicum Pharmaceuticals Inc
  • 13.4.1 Bellicum Pharmaceuticals Inc Company Details
  • 13.4.2 Bellicum Pharmaceuticals Inc Business Overview and Its Total Revenue
  • 13.4.3 Bellicum Pharmaceuticals Inc Adoptive Cellular Immunotherapy Introduction
  • 13.4.4 Bellicum Pharmaceuticals Inc Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
  • 13.4.5 Bellicum Pharmaceuticals Inc Recent Development
• 13.5 Bristol-Myers Squibb Co
  • 13.5.1 Bristol-Myers Squibb Co Company Details
  • 13.5.2 Bristol-Myers Squibb Co Business Overview and Its Total Revenue
  • 13.5.3 Bristol-Myers Squibb Co Adoptive Cellular Immunotherapy Introduction
  • 13.5.4 Bristol-Myers Squibb Co Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
  • 13.5.5 Bristol-Myers Squibb Co Recent Development
• 13.6 bluebird bio Inc
  • 13.6.1 bluebird bio Inc Company Details
  • 13.6.2 bluebird bio Inc Business Overview and Its Total Revenue
  • 13.6.3 bluebird bio Inc Adoptive Cellular Immunotherapy Introduction
  • 13.6.4 bluebird bio Inc Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
  • 13.6.5 bluebird bio Inc Recent Development
• 13.7 CARsgen Therapeutics Ltd
  • 13.7.1 CARsgen Therapeutics Ltd Company Details
  • 13.7.2 CARsgen Therapeutics Ltd Business Overview and Its Total Revenue
  • 13.7.3 CARsgen Therapeutics Ltd Adoptive Cellular Immunotherapy Introduction
  • 13.7.4 CARsgen Therapeutics Ltd Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
  • 13.7.5 CARsgen Therapeutics Ltd Recent Development
• 13.8 Celgene Corp
  • 13.8.1 Celgene Corp Company Details
  • 13.8.2 Celgene Corp Business Overview and Its Total Revenue
  • 13.8.3 Celgene Corp Adoptive Cellular Immunotherapy Introduction
  • 13.8.4 Celgene Corp Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
  • 13.8.5 Celgene Corp Recent Development
• 13.9 Cell Medica Ltd
  • 13.9.1 Cell Medica Ltd Company Details
  • 13.9.2 Cell Medica Ltd Business Overview and Its Total Revenue
  • 13.9.3 Cell Medica Ltd Adoptive Cellular Immunotherapy Introduction
  • 13.9.4 Cell Medica Ltd Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
  • 13.9.5 Cell Medica Ltd Recent Development
• 13.10 Cellular Biomedicine Group Inc
  • 13.10.1 Cellular Biomedicine Group Inc Company Details
  • 13.10.2 Cellular Biomedicine Group Inc Business Overview and Its Total Revenue
  • 13.10.3 Cellular Biomedicine Group Inc Adoptive Cellular Immunotherapy Introduction
  • 13.10.4 Cellular Biomedicine Group Inc Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
  • 13.10.5 Cellular Biomedicine Group Inc Recent Development
• 13.11 Celularity Inc
  • 10.11.1 Celularity Inc Company Details
  • 10.11.2 Celularity Inc Business Overview and Its Total Revenue
  • 10.11.3 Celularity Inc Adoptive Cellular Immunotherapy Introduction
  • 10.11.4 Celularity Inc Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
  • 10.11.5 Celularity Inc Recent Development
• 13.12 Celyad SA
  • 10.12.1 Celyad SA Company Details
  • 10.12.2 Celyad SA Business Overview and Its Total Revenue
  • 10.12.3 Celyad SA Adoptive Cellular Immunotherapy Introduction
  • 10.12.4 Celyad SA Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
  • 10.12.5 Celyad SA Recent Development
• 13.13 Daiichi Sankyo Co Ltd
  • 10.13.1 Daiichi Sankyo Co Ltd Company Details
  • 10.13.2 Daiichi Sankyo Co Ltd Business Overview and Its Total Revenue
  • 10.13.3 Daiichi Sankyo Co Ltd Adoptive Cellular Immunotherapy Introduction
  • 10.13.4 Daiichi Sankyo Co Ltd Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
  • 10.13.5 Daiichi Sankyo Co Ltd Recent Development
• 13.14 Fosun Pharmaceutical AG
  • 10.14.1 Fosun Pharmaceutical AG Company Details
  • 10.14.2 Fosun Pharmaceutical AG Business Overview and Its Total Revenue
  • 10.14.3 Fosun Pharmaceutical AG Adoptive Cellular Immunotherapy Introduction
  • 10.14.4 Fosun Pharmaceutical AG Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
  • 10.14.5 Fosun Pharmaceutical AG Recent Development
• 13.15 Gilead Sciences Inc
  • 10.15.1 Gilead Sciences Inc Company Details
  • 10.15.2 Gilead Sciences Inc Business Overview and Its Total Revenue
  • 10.15.3 Gilead Sciences Inc Adoptive Cellular Immunotherapy Introduction
  • 10.15.4 Gilead Sciences Inc Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
  • 10.15.5 Gilead Sciences Inc Recent Development
• 13.16 Guangzhou Anjie Biomedical Technology Co Ltd
  • 10.16.1 Guangzhou Anjie Biomedical Technology Co Ltd Company Details
  • 10.16.2 Guangzhou Anjie Biomedical Technology Co Ltd Business Overview and Its Total Revenue
  • 10.16.3 Guangzhou Anjie Biomedical Technology Co Ltd Adoptive Cellular Immunotherapy Introduction
  • 10.16.4 Guangzhou Anjie Biomedical Technology Co Ltd Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
  • 10.16.5 Guangzhou Anjie Biomedical Technology Co Ltd Recent Development
• 13.17 Hangzhou Converd Co Ltd
  • 10.17.1 Hangzhou Converd Co Ltd Company Details
  • 10.17.2 Hangzhou Converd Co Ltd Business Overview and Its Total Revenue
  • 10.17.3 Hangzhou Converd Co Ltd Adoptive Cellular Immunotherapy Introduction
  • 10.17.4 Hangzhou Converd Co Ltd Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
  • 10.17.5 Hangzhou Converd Co Ltd Recent Development
• 13.18 Hebei Senlang Biotechnology Inc Ltd
  • 10.18.1 Hebei Senlang Biotechnology Inc Ltd Company Details
  • 10.18.2 Hebei Senlang Biotechnology Inc Ltd Business Overview and Its Total Revenue
  • 10.18.3 Hebei Senlang Biotechnology Inc Ltd Adoptive Cellular Immunotherapy Introduction
  • 10.18.4 Hebei Senlang Biotechnology Inc Ltd Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
  • 10.18.5 Hebei Senlang Biotechnology Inc Ltd Recent Development
• 13.19 HRAIN Biotechnology Co Ltd
  • 10.19.1 HRAIN Biotechnology Co Ltd Company Details
  • 10.19.2 HRAIN Biotechnology Co Ltd Business Overview and Its Total Revenue
  • 10.19.3 HRAIN Biotechnology Co Ltd Adoptive Cellular Immunotherapy Introduction
  • 10.19.4 HRAIN Biotechnology Co Ltd Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
  • 10.19.5 HRAIN Biotechnology Co Ltd Recent Development
• 13.20 Juno Therapeutics Inc
  • 10.20.1 Juno Therapeutics Inc Company Details
  • 10.20.2 Juno Therapeutics Inc Business Overview and Its Total Revenue
  • 10.20.3 Juno Therapeutics Inc Adoptive Cellular Immunotherapy Introduction
  • 10.20.4 Juno Therapeutics Inc Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
  • 10.20.5 Juno Therapeutics Inc Recent Development
• 13.21 Kite Pharma Inc
  • 10.21.1 Kite Pharma Inc Company Details
  • 10.21.2 Kite Pharma Inc Business Overview and Its Total Revenue
  • 10.21.3 Kite Pharma Inc Adoptive Cellular Immunotherapy Introduction
  • 10.21.4 Kite Pharma Inc Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
  • 10.21.5 Kite Pharma Inc Recent Development
• 13.22 Nanjing Legend Biotech Co Ltd
  • 10.22.1 Nanjing Legend Biotech Co Ltd Company Details
  • 10.22.2 Nanjing Legend Biotech Co Ltd Business Overview and Its Total Revenue
  • 10.22.3 Nanjing Legend Biotech Co Ltd Adoptive Cellular Immunotherapy Introduction
  • 10.22.4 Nanjing Legend Biotech Co Ltd Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
  • 10.22.5 Nanjing Legend Biotech Co Ltd Recent Development
• 13.23 NantKwest Inc
  • 10.23.1 NantKwest Inc Company Details
  • 10.23.2 NantKwest Inc Business Overview and Its Total Revenue
  • 10.23.3 NantKwest Inc Adoptive Cellular Immunotherapy Introduction
  • 10.23.4 NantKwest Inc Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
  • 10.23.5 NantKwest Inc Recent Development
• 13.24 Nkarta Inc
  • 10.24.1 Nkarta Inc Company Details
  • 10.24.2 Nkarta Inc Business Overview and Its Total Revenue
  • 10.24.3 Nkarta Inc Adoptive Cellular Immunotherapy Introduction
  • 10.24.4 Nkarta Inc Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
  • 10.24.5 Nkarta Inc Recent Development
• 13.25 Novartis AG
  • 10.25.1 Novartis AG Company Details
  • 10.25.2 Novartis AG Business Overview and Its Total Revenue
  • 10.25.3 Novartis AG Adoptive Cellular Immunotherapy Introduction
  • 10.25.4 Novartis AG Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
  • 10.25.5 Novartis AG Recent Development
• 13.26 Ono Pharmaceutical Co Ltd
  • 10.26.1 Ono Pharmaceutical Co Ltd Company Details
  • 10.26.2 Ono Pharmaceutical Co Ltd Business Overview and Its Total Revenue
  • 10.26.3 Ono Pharmaceutical Co Ltd Adoptive Cellular Immunotherapy Introduction
  • 10.26.4 Ono Pharmaceutical Co Ltd Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
  • 10.26.5 Ono Pharmaceutical Co Ltd Recent Development
• 13.27 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
  • 10.27.1 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Company Details
  • 10.27.2 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Business Overview and Its Total Revenue
  • 10.27.3 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Adoptive Cellular Immunotherapy Introduction
  • 10.27.4 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
  • 10.27.5 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Recent Development
• 13.28 Sorrento Therapeutics Inc
  • 10.28.1 Sorrento Therapeutics Inc Company Details
  • 10.28.2 Sorrento Therapeutics Inc Business Overview and Its Total Revenue
  • 10.28.3 Sorrento Therapeutics Inc Adoptive Cellular Immunotherapy Introduction
  • 10.28.4 Sorrento Therapeutics Inc Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
  • 10.28.5 Sorrento Therapeutics Inc Recent Development
• 13.29 Takara Bio Inc
  • 10.29.1 Takara Bio Inc Company Details
  • 10.29.2 Takara Bio Inc Business Overview and Its Total Revenue
  • 10.29.3 Takara Bio Inc Adoptive Cellular Immunotherapy Introduction
  • 10.29.4 Takara Bio Inc Revenue in Adoptive Cellular Immunotherapy Business (2015-2020)
  • 10.29.5 Takara Bio Inc Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer